Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02419560 | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | completed | Phase 1 | 37 | Craig Portell, MDOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03302728 | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma(EpiBrentlen) | completed | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT03682796 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | completed | Phase 1 | 32 | Triphase Research and Development III Corp.INDUSTRY | 2 | May 19, 2022 | clinicaltrials |
| NCT02395601 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | completed | Phase 1 | 41 | Constellation PharmaceuticalsINDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT03141203 | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients(RomiCar) | completed | Phase 1 / Phase 2 | 50 | University of BirminghamOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT00416351 | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02429375 | Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02584920 | A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | completed | Phase 1 / Phase 2 | 87 | Shanghai Henlius BiotechINDUSTRY | 0 | May 9, 2022 | clinicaltrials |
| NCT03218072 | A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas | completed | Phase 1 | 12 | Shanghai Henlius BiotechINDUSTRY | 0 | May 9, 2022 | clinicaltrials |
| NCT04944771 | Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | May 9, 2022 | clinicaltrials |
| NCT02468687 | NMP in Relapsed / Refractory Myeloma | completed | Phase 1 | 13 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03288480 | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 24 | Promontory Therapeutics Inc.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02514668 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | completed | Phase 1 | 55 | SanofiINDUSTRY | 3 | Apr 25, 2022 | clinicaltrials |
| NCT02631577 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma(KPT-330+RICE) | completed | Phase 1 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03563560 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia(AML) | completed | Phase 1 | 10 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | completed | Phase 1 | 53 | Cancer Research UKOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 7 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | completed | Phase 1 / Phase 2 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT01411267 | AC220 for Children With Relapsed/Refractory ALL or AML | completed | Phase 1 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma(MEDI2228) | completed | Phase 1 | 107 | MedImmune LLCINDUSTRY | 4 | Mar 28, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04163107 | Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma(MYELOMA-HCQ) | completed | Phase 1 | 19 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04888468 | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | completed | Phase 1 | 9 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03464916 | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 7 | Corvus Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT01433965 | Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 16 | University of California, DavisOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | completed | Phase 1 | 10 | Mehrdad Abedi, MDOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03315039 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 7 | Moleculin Biotech, Inc.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | completed | Phase 1 / Phase 2 | 77 | NS Pharma, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03974243 | Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | completed | Phase 1 | 120 | Xencor, Inc.INDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04260932 | CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients | completed | Phase 1 | 12 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04260945 | CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients | completed | Phase 1 | 12 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT00667329 | Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | completed | Phase 1 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT00951457 | Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 20 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03925935 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | completed | Phase 1 | 42 | Angiocrine BioscienceINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04327037 | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | completed | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02514239 | Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 2 | Feb 24, 2022 | clinicaltrials |
| NCT01583283 | Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02086604 | Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | Phase 1 | 37 | Washington University School of MedicineOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01893320 | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 9, 2022 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2022source: clinicaltrials